MLH1 and cancer: The lifetime risks of cancer are significantly higher in MSH2 and MLH1 mutation carriers compared to carriers of MSH6 or PMS2 mutations, which may reflect functional redundancy of MSH6 (with MSH3) and PMS2 (with MLH3 and PMS1) (see above).